Merck discontinues late-stage trial of experimental lung cancer treatment after high number of adverse events
Merck & Co. said Thursday it’s discontinuing a late-stage trial of a treatment for patients with extensive-stage small cell lung cancer after patients experienced a high rate of adverse events.